**Title**: Incidence and Risk of Post-COVID-19 Thromboembolic Disease and the Impact of Aspirin Prescription; Nationwide Observational Cohort at the US Department of Veteran Affairs.

**Short title**: Incidence and Risk of Post-COVID-19 Thromboembolic Disease and the Impact of Aspirin Prescription

## Authors:

- 1. Anna D Ware<sup>1</sup>
- 2. Zachary P Veigulis<sup>1,2</sup>
- 3. Peter J Hoover<sup>1</sup>
- 4. Terri L Blumke<sup>1</sup>
- 5. George N Ioannou<sup>4,5</sup>
- 6. Edward J Boyko<sup>6</sup>
- 7. Thomas F Osborne<sup>1,3</sup>

### Affiliations:

- 1. National Center for Collaborative Healthcare Innovation, VA Palo Alto Healthcare System, Palo Alto, CA, USA
- 2. Department of Business Analytics, University of Iowa Tippie College of Business, Iowa City, IA, USA
- 3. Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
- 4. Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Healthcare System, Seattle, WA
- 5. Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA
- 6. Seattle Epidemiologic Research and Information Center, Veterans Affairs Puget Sound Healthcare System, Seattle, WA

#### **Corresponding Author:**

Anna D. Ware, MPH 3801 Miranda Ave, Palo Alto, CA, USA, 94304 +1(612)369-2790 <u>Anna.Ware@va.gov</u>

#### Word Count: 3,000

Key Words: COVID-19, Aspirin, Thromboembolism, Thrombosis, Pulmonary Embolism

Conflict of Interest Statement: The authors report no conflict of interest.

**Disclaimer**: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Department of Veterans Affairs.

## Abstract

**Introduction:** COVID-19 triggers prothrombotic and proinflammatory changes, with thrombotic disease prevalent in up to 30% SARS-CoV-2 infected patients. Early work suggests that aspirin could prevent COVID-19 related thromboembolic disorders in some studies but not others. This study leverages data from the largest integrated healthcare system in the United States to better understand this association. Our objective was to evaluate the incidence and risk of COVID-19 associated acute thromboembolic disorders and the potential impact of aspirin.

**Methods**: This retrospective, observational study utilized national electronic health record data from the Veterans Health Administration. 334,374 Veterans who tested positive for COVID-19 from March 2, 2020, to June 13, 2022, were included, 81,830 of whom had preexisting aspirin prescription prior to their COVID-19 diagnosis. Patients with and without aspirin prescriptions were matched and the odds of post-COVID acute thromboembolic disorders were assessed.

**Results:** 10.1% of Veterans had a documented thromboembolic disorder within 12 months following their COVID-19 diagnosis. Those with specific comorbidities were at greatest risk. Preexisting aspirin prescription was associated with a significant decrease risk of post-COVID-19 thromboembolic disorders, including pulmonary embolism (OR [95% CI]: 0.69 [0.65, 0.74]) and deep vein thrombosis (OR [95% CI]: 0.76 [0.69, 0.83], but an increased risk of acute arterial diseases, including ischemic stroke (OR [95% CI]: 1.54 [1.46, 1.60]) and acute ischemic heart disease (1.33 [1.26, 1.39]).

**Conclusions:** Findings demonstrated that preexisting aspirin prescription prior to COVID-19 diagnosis was associated with significantly decreased risk of venous thromboembolism and pulmonary embolism but increased risk of acute arterial disease. The risk of arterial disease may be associated with increased COVID-19 prothrombotic effects superimposed on preexisting chronic cardiovascular disease for which aspirin was already prescribed. Prospective clinical trials may help to further assess the efficacy of aspirin use prior to COVID-19 diagnosis for the prevention of post-COVID-19 thromboembolic disorders.

#### Introduction

As of June 13<sup>th</sup>, 2023, an estimated 879,548 Veterans have been infected with SARS-CoV2, with 24,777 known COVID-19 deaths, and many suffering the long-term effects of the infection.<sup>1,2</sup> Early in the pandemic, major health impacts of the disease were thought to be the consequence of the associated severe viral pneumonia.<sup>3,4</sup> Since then, evidence demonstrates that COVID-19 triggers prothrombotic and proinflammatory changes throughout the body which can have multi-systemic adverse outcomes during and after acute infection.<sup>5,6,7,8,9,10</sup> In fact, multiple clinical trials and observational studies have documented thrombotic disease in 25–30% SARS-CoV-2 infected patients, primarily in seriously ill patients.<sup>11,12,13,14,15,16,17,18</sup> Other researcher suggest that aspirin use could prevent post-COVID acute thromboembolic disorders, although results thus far have been mixed.<sup>19,20,21</sup> Without further evidence, current clinical guidelines recommend that patients diagnosed with COVID-19 do not initiate low-dose antiplatelet therapy (i.e., aspirin) for the prevention of thromboembolism associated with COVID-19.<sup>22</sup>

The Veterans Health Administration (VHA) is the largest integrated healthcare system in the United States (U.S.), providing care for over 9 million enrolled Veterans.<sup>23</sup> Veterans represent a statistically older population with multiple comorbidities and are therefore at greater risk for COVID-19 complications and poorer outcomes compared to the general public.<sup>24</sup> The aims of this study were to 1) assess the incidence of COVID-19 associated acute thromboembolic disorders, 2) identify risk factors for post-acute COVID-19 thromboembolic disorders, and 3) quantify the potential impact that preexisting aspirin use had on the risk of thromboembolic disease.

### **Materials and Methods**

## Data Source and Patients

We performed a retrospective observational analysis from March 2<sup>nd</sup>, 2020, until June 13<sup>th</sup>, 2022, of Veterans aged 18 years or older who were diagnosed with COVID-19 using data from the VHA's electronic health record (EHR) database, the Corporate Data Warehouse (CDW).<sup>25</sup> Queries were developed to extract and collate patient demographic and clinical information.

Patients with documented COVID-19 polymerase chain reaction (PCR) lab test from March 2<sup>nd</sup>, 2020, until June 13<sup>th</sup>, 2022, were identified. A 12-month follow-up period following the patient's first positive COVID-19 PCR test for incidence of post-COVID-19 acute thromboembolic disorders was included, making the full assessment timeline from March 2<sup>nd</sup>, 2020, until June 13<sup>th</sup>, 2023. Patients with a negative or not-detected test result, those with a non-PCR or antigen lab, or patients with an incomplete Care Assessment Needs (CAN) score within 6 months prior to their COVID-19 PCR test were excluded from the analysis (cohort inclusion/exclusion flowchart depicted in **Figure 1**). The CAN score is automatically calculated weekly on all living Veterans assigned to primary care panels.<sup>26,27</sup> It was utilized to inform current health status as well as identify patients actively utilizing VA care.

## Variables

The first documented positive COVID-19 PCR test during the patient's latest episode of SARS-CoV2 infection was captured as the index date. For example, if a patient tested positive for COVID-19 in March

2020, then again in August 2021, with positive tests every two weeks through October 2021 for the 2nd infection, we captured the positive test in August 2021 as our index date.

Similar to methodologies established elsewhere, VHA's EHR data was utilized to assess aspirin use.<sup>4,28</sup> In short, aspirin use was defined as patients with an active aspirin prescription at the time of their index date. If a patient had no refills at this time, the prescription was only considered active if it was filled up to 30 days prior to the index date. Patients who had an active non-VHA aspirin prescription documented in their EHR were also included in the aspirin cohort. All other patients in the cohort with no documented active aspirin prescription were classified as controls.

Thromboembolic disorders were captured using ICD-10 codes within the patient's EHR. This included venous thromboembolic disorders (pulmonary embolism (PE), deep vein thrombosis (DVT), cerebral venous sinus thrombosis (CVST), and other venous thromboembolic disorders), as well as arterial thromboembolic disorders (ischemic stroke, ischemic heart disease, and other arterial thromboembolic disorders). ICD-10 codes and definitions can be found in **Supp Table 1**.

Additional covariates included age, sex, self-identified race or ethnicity, the CAN 1-Year Mortality score (Model Version 2.5), the Charlson Comorbidity Index (CCI), body mass index (BMI), common comorbidities, inpatient status at index date, vaccination status and number of vaccine doses at the index date, and all-cause mortality within the follow-up period. The CAN score incorporates multiple structured data elements, including socio-demographics, diagnoses, vital signs, medications, lab values, and healthcare utilization data in its calculation and was utilized to quantify a patient's health risk. The score ranges from 0 to 99, with higher scores representing a greater risk of mortality.<sup>4,276,29</sup>

# Statistical Analysis

To assess post-COVID-19 acute thromboembolic disorders, contingency tables and unadjusted odds ratios were analyzed for any associations between the aspirin and control groups using the complete cohort. To mitigate potential confounding effects resulting from the retrospective observational nature of our dataset, propensity score matching (PSM) was utilized to match and compare patients in the aspirin vs control groups using the "nearest-neighbor" method within the RStudio "Matchlt" library (Version 3.6.2)<sup>30</sup> on the unscaled covariates of age, gender, and CAN score. Vaccination status was not included as a covariate in the matching algorithm since our assessment demonstrated that it was not significantly associated with the treatment assignment nor the outcome. We then produced contingency tables and adjusted odds ratios for post-COVID-19 acute thromboembolic disorders. Odds ratios are reported as point estimates with 95% confidence intervals for the aspirin cohort with the control cohort as reference.

To identify Veterans at highest risk for post-COVID-19 acute thromboembolic disorders, we examined the association of each outcome subgroup using multivariate logistic regression models adjusting for the covariates of age, sex, BMI, CCI, race and/or ethnicity, and common comorbidities prior to the index date as a sub-analysis using the complete cohort. The CAN score was not included in this part of the analysis due to multicollinearity.

This study was approved by Stanford Institutional Review Board (Stanford University, Stanford, CA, USA; IRB #60725). Given the retrospective nature of our study and the minimal risk it posed to participants,

the Stanford IRB granted this study a waiver for informed consent. This decision aligns with the ethical standards set forth in the 1964 Helsinki declaration and its later amendments, ensuring that all study procedures were conducted with the utmost respect for participant rights and privacy.

# Results

# **Baseline Patient Characteristics**

Of the 334,374 COVID-19 Veterans in our cohort, 24.5% had an active aspirin prescription prior to their index date (**Figure 1**). There was significant variation between groups at baseline in the complete cohort, demonstrating the need for PSM (**Table 1**). After PSM, 163,660 patients (81,830 aspirin users and non-users) were included in the analysis with an average (SD) age was 69.6 (10.8) years, 94.4% were male, and average (SD) CAN score was 57.3 (26.7). Density plots of the matched covariates demonstrate optimal balance after PSM (**Supp Figure 1**).

# Figure 1 Caption: Patient Flowchart

# Risk Factors for Post-COVID-19 Acute Thromboembolic Disorders

In our sub-analysis using the complete cohort prior to PSM, those with an incidence of any post COVID-19 thromboembolic disorders vs not, were prior diagnoses of congestive heart failure (CHF) (34.7% vs. 11.7%), chronic pulmonary disease (52.3% vs. 34.4%), CKD (35.4% vs. 14.2%), and hypertension (HTN) (89.7% vs. 58.8%; **Supp Table 2**). When assessing the odds of any thromboembolic disorders in the complete cohort, there was an increased risk among older patients (OR [95% CI]: 1.03 [1.03, 1.03]), Black or African Americans (1.12 [1.08, 1.15]), male (1.26 [1.20, 1.33]), and for those diagnosed with CHF (1.45 [1.41, 1.50]), or HTN (1.56 [1.50, 1.62]) across all subgroups of thromboembolic disorders (**Supp Figure 2**).

## Post-COVID-19 Acute Thromboembolic Disorders

Prior to PSM, 10.1% of Veterans had a condition typically related to thromboembolic disease within the follow-up period (**Table 2**). This increased to 14.4% after matching on key baseline characteristics. The most prevalent among the case and control groups, respectively were ischemic stroke (6.9% vs. 4.6%, p<0.001), ischemic heart disease (4.8% vs. 3.7%, p<0.001), PE (2.1% vs. 3.0%, p<0.001), other venous thromboembolic disorders (2.1% vs. 2.8%, p<0.001), other arterial thromboembolic disorders (1.7% vs 1.3%, p<0.001), and DVT (1.1% vs. 1.3%, p<0.001).

## Aspirin's Relationship with Post-COVID-19 Acute Thromboembolic Disorders

After PSM, aspirin use was associated with decreased risk of PE (OR [95% CI]: 0.69 [0.65, 0.74]), DVT (0.76 [0.69, 0.83]) and other venous thromboembolic disorders (0.73 [0.69, 0.78]; **Table 3 & Figure 2**). However, there was an increased risk of post-COVID-19 arterial diseases, including ischemic stroke (OR [95% CI]: 1.54 [1.46, 1.60]), acute ischemic heart disease (1.33 [1.26, 1.39]), and other arterial thromboembolic disorders (1.32 [1.22, 1.43]).

Figure 2 Caption. Forest Plot displaying the association (odds ratio [95% CI]) between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disorders within the follow-up period among the propensity score matched cohort (N=168010).

## Discussion

COVID-19 can trigger systemic inflammatory and prothrombotic changes in the body, leading to negative adverse acute and long-term outcomes including cardiovascular disease.<sup>9-15</sup> As a result, researchers have speculated that aspirin could prevent some of the debilitating post-COVID-19 conditions such as thromboembolic disorders.<sup>5-8</sup> However, results have varied thus far and have been inconclusive.<sup>20,21</sup> This study leveraged historical operational data from over 330,000 medical records, at the largest integrated healthcare system within the U.S., to help clarify associations.

We found that 10.1% of our cohort were diagnosed with post-acute COVID-19 thromboembolic disorders within 12-months following their SARS-CoV2 infection. This rate is significantly greater than the expected baseline yearly incidence of thromboembolic disorders,<sup>31</sup> yet similar to other reports of post COVID-19 thrombotic disease incidence.<sup>14</sup> Overall risk factors most strongly associated with post-COVID-19 acute thromboembolic disorders include older patients, males, those self-identified as Black or African American, and those with comorbidities such as CHF and HTN.

Interestingly, our findings demonstrate opposite venous and arterial thromboembolic disease risk associations for those taking aspirin vs not prior to being diagnosed with COVID-19. Specifically, COVID-19 positive Veterans with preexisting aspirin prescriptions had a decreased risk of venous thromboembolic disorders, but an increased risk of arterial thromboembolic diseases during the followup period. Because daily aspirin use is typically prescribed as a prophylaxis for arterial thromboembolic disease,<sup>32</sup> these arterial disease results could potentially reflect the biased baseline population risks in the aspirin group. Therefore, Veterans who were predetermined to be at increased risk for arterial disease by their clinician and prophylactically taking aspirin to reduce that risk may have a superimposed higher risk during a prothrombotic state from COVID-19 that the antithrombotic effects of aspirin could not overcome.

Strengths of this study include the large population-based assessment of Veterans, utilizing data from a nationwide integrated healthcare system, in which diagnoses, medication use, and laboratory studies are all observable. VHA is in a unique position to assess OTC medications because VHA can directly provide Veterans with OTC medications and systematically documents all active medications for those who acquire OTCs elsewhere. Additionally, while a handful of previous studies attempted to assess the effects of aspirin on post-COVID thromboembolic disorders,<sup>20,21</sup> there were limitations in the ability to distinguish between historical, chronic, and acute aspirin uses. In contrast, our assessment presents associations for our cohort who were prescribed daily aspirin prior to their COVID-19 diagnosis, and not as a new or historical-inactive treatment.

Our results are limited as our Veteran population may face unique Veteran related health challenges,<sup>1</sup> therefore, these associations may not be generalizable to non-VHA settings. Although our PSM models demonstrated balance across covariates, it was not able to eliminate the expected confounding that was related to the association of daily aspirin being prescribed to those who are clinically determined to be

at higher risk for cardiovascular disease. As this is a retrospective evaluation, we cannot establish direct cause and effect, and therefore future randomized-control trials required to assess the potential of aspirin as a drug repurposing option to prevent post-COVID acute thromboembolic disorders.

#### Conclusion:

Preexisting aspirin prescription at the time of COVID-19 diagnosis was associated with significantly decreased risk of venous thromboembolic disorders and an increased risk of arterial thromboembolic disease. The risk of arterial disease may, in part, be associated with preexisting arterial disease that triggered the historical daily aspirin prescription before COVID-19 diagnosis. Prospective clinical trials are required to assess the efficacy and appropriateness of aspirin use prior to COVID-19 diagnosis for the prevention of acute post-COVID-19 thromboembolic disorders.

# **Exhibits (Tables/Figures)**

### Table 1. Patient Characteristics Before and After Propensity Score Matching

	Complet	e Cohort	Propensity Score	Matched Cohort
	Non-Users (N=252544)	Aspirin Users (N= 81830)	Non-Users (N=81830)	Aspirin Users (N=81830)
Matched Patient Characteristics				
Age (years), mean (SD)	57.7 (16.4)	69.6 (10.8)	69.6 (10.8)	69.6 (10.8)
Male	217090 (86.0%)	77245 (94.4%)	77245 (94.4%)	77245 (94.4%)
CAN 1 Year Mortality Score, mean (SD)	38.8 (30.3)	57.3 (26.7)	57.3 (26.7)	57.3 (26.7)
Non-Matched Patient Characteristics				
Race and/or Ethnicity				
Non-Hispanic White	140166 (55.5%)	50167 (61.3%)	49468 (60.5%)	50167 (61.3%)
Non-Hispanic Black or African American	59295 (23.5%)	18775 (22.9%)	18778 (22.9%)	18775 (22.9%)
Hispanic	28784 (11.4%)	6442 (7.9%)	6673 (8.2%)	6442 (7.9%)
Asian	3767 (1.5%)	660 (0.8%)	643 (0.8%)	660 (0.8%)
American Indian or Alaska Native	2638 (1.0%)	779 (1.0%)	813 (1.0%)	779 (1.0%)
Native Hawaiian/Other Pacific Islander	2266 (0.9%)	687 (0.8%)	659 (0.8%)	687 (0.8%)
Declined	12178 (4.8%)	3711 (4.5%)	3864 (4.7%)	3711 (4.5%)
Missing	3450 (1.4%)	609 (0.7%)	932 (1.1%)	609 (0.7%)
Aspirin Dosage (mg/day), mean (SD)	NA	98.4 (61.9)	NA	98.4 (61.9)
81 mg/day	NA	76976 (91.6%)	NA	76976 (91.6%
162 mg/day	NA	1172 (1.4%)	NA	1172 (1.4%)
243 mg/day	NA	50 (0.1%)	NA	50 (0.1%)
325 mg/day	NA	3022 (3.7%)	NA	3022 (3.7%)
405-650 mg/day	NA	45 (0.0%)	NA	45 (0.0%)
No Dose Listed (Non-VA prescription)	NA	565 (0.7%)	NA	565 (0.7%)
CCI Score, mean (SD)	2.23 (2.90)	4.14 (3.21)	3.92 (3.22)	4.14 (3.21)
Body Mass Index (BMI), mean (SD)	30.8 (6.42)	30.6 (6.24)	29.9 (6.29)	30.6 (6.24)
Common Comorbidities Prior to COVID-19 Diagnosis				
Congestive Heart Failure	26305 (10.4%)	20604 (25.2%)	14140 (17.3%)	20604 (25.2%
Chronic Pulmonary Disease	82704 (32.7%)	38334 (46.8%)	35478 (43.4%)	38334 (46.8%)
Chronic Kidney Disease	33428 (13.2%)	21198 (25.9%)	17295 (21.1%)	21198 (25.9%)
Diabetes	32874 (13.0%)	16500 (20.2%)	13778 (16.8%)	16500 (20.2%)
Hypertension	134755 (53.4%)	71040 (86.8%)	59741 (73.0%)	71040 (86.8%)
npatient for COVID-19	78586 (31.1%)	35212 (43.0%)	35057 (42.8%)	35212 (43.0%)
Vaccinated status for COVID-19				
Unvaccinated at time of COVID diagnosis	173230 (68.6%)	55193 (67.4%)	55693 (68.1%)	56602 (67.4%
Vaccinated at time of COVID diagnosis	79314 (31.4%)	26637 (32.6%)	26137 (31.9%)	27403 (32.6%
Number Vaccine Doses prior to COVID-19 Diagnosis				
Unvaccinated	173230 (68.6%)	55193 (67.4%)	55693 (68.1%)	55193 (67.4%)
1 Dose	8855 (3.5%)	2157 (2.6%)	2345 (2.9%)	2157 (2.6%)
2 Doses	37887 (15.0%)	10879 (13.3%)	10869 (13.3%)	10879 (13.3%)

3 Doses	32572 (12.9%)	13601 (16.6%)	12923 (15.8%)	13601 (16.6%)
Death within follow-up period	26254 (10.4%)	7531 (9.2%)	13890 (17.0%)	7531 (9.2%)

CAN = Care Assessment Needs, CCI = Charelson Comorbidity Index

\*Propensity Score Matching was performed using the "nearest neighbor" method in R Studio (Version 3.6.2) through the "MatchIt" library, matching on the covariates of age, gender, and the VA's Care Assessment of Needs (CAN) 1-Year Mortality Score.

· · · ·			<b>U</b>				•	
	Complete Unmatched Cohort			PSM Matched Cohort*				
	Overall (N=334,374)	Non- Aspirin (N=252544)	Aspirin Users (N=81830)	p- value⁺	Overall (N=163660)	Non- Aspirin (N=81830)	Aspirin Users (N=81830)	p- value⁺
Any Thromboembolic Disorders	33925 (10.1%)	21233 (8.4%)	12692 (15.5%)	< 0.001	23643 (14.4%)	10951 (13.4%)	12692 (15.5%)	<0.001
Venous Thromboembolic Disorders								
Pulmonary Embolism	6728 (2.0%)	5021 (2.0%)	1707 (2.1%)	0.223	4148 (2.5%)	2441 (3.0%)	1707 (2.1%)	<0.001
Deep Vein Thrombosis	3206 (1.0%)	2336 (0.9%)	870 (1.1%)	0.002	1949 (1.2%)	1079 (1.3%)	870 (1.1%)	<0.001
Cerebral Venous Sinus Thrombosis	75 (0.0%)	53 (0.0%)	22 (0.0%)	0.619	39 (0.0%)	17 (0.0%)	22 (0.0%)	0.726
Other Venous Thromboembolic Disorders <sup>1</sup>	6289 (1.9%)	4594 (1.8%)	1695 (2.1%)	<0.001	3947 (2.4%)	2252 (2.8%)	1695 (2.1%)	<0.001
Arterial Thromboembolic Disorders								
Ischemic Stroke	12532 (3.7%)	6867 (2.7%)	5665 (6.9%)	<0.001	9432 (5.8%)	3767 (4.6%)	5665 (6.9%)	<0.001
Ischemic Heart Disease (STEMI/NSTEMI)	9626 (2.9%)	5676 (2.2%)	3950 (4.8%)	<0.001	6964 (4.3%)	3014 (3.7%)	3950 (4.8%)	<0.001
Other Arterial Thromboembolic Disorders <sup>2</sup>	3314 (1.0%)	1911 (0.8%)	1403 (1.7%)	<0.001	2472 (1.5%)	1069 (1.3%)	1403 (1.7%)	<0.001

Table 2. Frequency of post-COVID-19 acute thromboembolic disorders among aspirin users vs. non-users within 12 months following index date.

\*Propensity Score Matching (PSM) was performed using the "nearest neighbor" method in R Studio (Version 3.6.2) through the "MatchIt" library, matching on the covariates of age, gender, and the VA's Care Assessment of Needs (CAN) 1-Year Mortality Score.

<sup>+</sup>Chi-Sq and T-test used to determine significant associations between groups.

<sup>1</sup>Other Venous Thromboembolic Disorders includes acute embolism and thrombosis of the axillary, subclavian, internal jugular, superior vena cava, inferior vena cava, renal, and other thoracic veins. Also, acute embolism and thrombosis of other specified deep veins of lower extremities and veins of upper extremities.

<sup>2</sup>Other Arterial Thromboembolic Disorders includes both arterial embolism and thrombosis, and renal embolism and thrombosis.

**Table 3**. Unadjusted and adjusted odds ratios (95% confidence interval) for associations between patients who were prescribed aspirin at baseline and the occurrence of post-COVID-19 acute thromboembolic disorders within the follow-up period.

	Complete Unmatched Cohort (N=334374)	PSM Matched Cohort* (N= 163660)	
	Unadjusted ORs (95% Cls)	Adjusted ORs (95% Cls)	
Any Thromboembolic Disorders	2.00 (1.95, 2.05)	1.19 (1.16, 1.22)	
Venous Thromboembolic Disorders			
Pulmonary Embolism	1.05 (0.99, 1.11)	0.69 (0.65, 0.74)	
Deep Vein Thrombosis	1.15 (1.06, 1.24)	0.76 (0.69, 0.83)	
Cerebral Venous Sinus Thrombosis	1.28 (0.76, 2.08)	1.05 (0.56, 1.99)	
Other Venous Thromboembolic Disorders <sup>1</sup>	1.14 (1.07, 1.20)	0.73 (0.69, 0.78)	
Arterial Thromboembolic Disorders			
Ischemic Stroke	2.66 (2.59, 2.78)	1.54 (1.47, 1.60)	
Acute Ischemic Heart Disease (STEMI/NSTEMI)	2.21 (2.12, 2.30)	1.33 (1.26, 1.39)	
Other Arterial Thromboembolic Disorders <sup>2</sup>	2.29 (2.13, 2.45)	1.32 (1.22, 1.43)	

Significant odds ratios (OR) are bolded (p<0.05

\*Propensity Score Matching (PSM) was performed using the "nearest neighbor" method in R Studio (Version 3.6.2) through the "MatchIt" library, matching on the covariates of age, gender, and the VA's Care Assessment of Needs (CAN) 1-Year Mortality Score.

\*\*Adjusted for CAN 1-Year Mortality Score, Male, and Age in models prior to PSM matching

<sup>1</sup>Other Venous Thromboembolic Disorders includes acute embolism and thrombosis of the axillary, subclavian, internal jugular, superior vena cava, inferior vena cava, renal, and other thoracic veins. Also, acute embolism and thrombosis of other specified deep veins of lower extremities and veins of upper extremities.

<sup>2</sup>Other Arterial Thromboembolic Disorders includes arterial embolism and thrombosis and renal embolism and thrombosis.

#### References

<sup>1</sup> COVID-19 National Summary | Veterans Affairs.

https://www.accesstocare.va.gov/Healthcare/COVID19NationalSummary. Accessed June 13<sup>th</sup>, 2023 <sup>2</sup> Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur Heart J. 2022 Mar 14;43(11):1157-1172. doi: 10.1093/eurheartj/ehac031. PMID: 35176758; PMCID: PMC8903393.

<sup>3</sup> Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, Sohail MR, Mahmood SF, Ochani R, Hussham Arshad M, Kumar A, Surani S. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021 Mar 1;29(1):20-36. PMID: 33664170.

<sup>4</sup> Osborne TF, Veigulis ZP, Arreola DM, Mahajan SM, Röösli E, Curtin CM. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS One. 2021 Feb 11;16(2):e0246825. doi: 10.1371/journal.pone.0246825. PMID: 33571280; PMCID: PMC7877611.

<sup>5</sup> Restrepo MI, Marin-Corral J, Rodriguez JJ, Restrepo V, Cavallazzi R. Cardiovascular Complications in Coronavirus Disease 2019-Pathogenesis and Management. Semin Respir Crit Care Med. 2023 Feb;44(1):21-34. doi: 10.1055/s-0042-1760096. Epub 2023 Jan 16. PMID: 36646083.

<sup>6</sup> Violi F, Cammisotto V, Pignatelli P. Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. Platelets. 2021 Nov 17;32(8):1009-1017. doi: 10.1080/09537104.2021.1936478. Epub 2021 Jun 7. PMID: 34097572; PMCID: PMC8204311.

<sup>7</sup> Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M, McManus D, Wang SY, Price C, Bona RD, Ochoa Chaar CI, Chun HJ, Pine AB, Rinder HM, Siner JM, Neuberg DS, Owusu KA, Lee AI. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol. 2021 Apr 1;96(4):471-479. doi: 10.1002/ajh.26102. Epub 2021 Feb 22. PMID: 33476420; PMCID: PMC8013588.

<sup>8</sup> Al Harthi AF, Aljuhani O, Korayem GB, Altebainawi AF, Alenezi RS, Al Harbi S, Gramish J, Kensara R, Hafidh A, Al Enazi H, Alawad A, Alotaibi R, Alshehri A, Alhuthaili O, Vishwakarma R, Bin Saleh K, Alsulaiman T, Alqahtani RA, Hussain S, Almazrou S, Al Sulaiman K. Evaluation of Low-Dose Aspirin use among Critically III Patients with COVID-19: A Multicenter Propensity Score Matched Study. J Intensive Care Med. 2022 Sep;37(9):1238-1249. doi: 10.1177/08850666221093229. Epub 2022 Apr 21. PMID: 35450493; PMCID: PMC9038962.

<sup>9</sup> Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Bertuzzi A, Sandri MT, Barco S; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020 Jul;191:9-14. doi:

10.1016/j.thromres.2020.04.024. Epub 2020 Apr 23. PMID: 32353746; PMCID: PMC7177070.

 <sup>10</sup> Ma, S., Su, W., Sun, C. et al. Does aspirin have an effect on risk of death in patients with COVID-19? A metaanalysis. Eur J Clin Pharmacol 78, 1403–1420 (2022). https://doi.org/10.1007/s00228-022-03356-5
<sup>11</sup> Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. (2020) 191:145–7. doi: 10.1016/j.thromres.2020.04.013

<sup>12</sup> Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. *Ann Intern Med*. (2020). doi: 10.7326/M20-2003

<sup>13</sup> Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J Thromb Haemost*. (2020) 18:1421–4. doi: 10.1111/jth.14830

<sup>14</sup> Violi F, Cammisotto V, Pignatelli P. Thrombosis in Covid-19 and non-Covid-19 pneumonia: role of platelets. Platelets. 2021 Nov 17;32(8):1009-1017. doi: 10.1080/09537104.2021.1936478. Epub 2021 Jun 7. PMID: 34097572; PMCID: PMC8204311.

<sup>15</sup> Xie, Y., Xu, E., Bowe, B. et al. Long-term cardiovascular outcomes of COVID-19. Nat Med 28, 583–590 (2022). https://doi.org/10.1038/s41591-022-01689-3

<sup>16</sup> Wu T., Zuo Z., Yang D., Luo X., Jiang L., Xia Z., et al. (2021). Venous Thromboembolic Events in Patients with COVID-19: A Systematic Review and Meta-Analysis. Age Ageing 50 (2), 284–293. 10.1093/ageing/afaa259

<sup>17</sup> Piazza G, Campia U, Hurwitz S, et al. Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. J Am Coll Cardiol. 2020 Nov, 76 (18) 2060–2072. doi.org/10.1016/j.jacc.2020.08.070
<sup>18</sup> Middeldorp, S, Coppens, M, van Haaps, TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020; 18: 1995– 2002. https://doi.org/10.1111/jth.14888
<sup>19</sup> Chuang YC, Tsai HW, Liu SA, Wu MJ, Liu PY. COVID-19 in Veterans: A Narrative Review. Risk Manag Healthc Policy. 2022 Apr 26;15:805-815. doi: 10.2147/RMHP.S354814. PMID: 35502442; PMCID: PMC9056054.
<sup>20</sup>Zareef R, Diab M, Al Saleh T, Makarem A, Younis NK, Bitar F, Arabi M. Aspirin in COVID-19: Pros and Cons. Front Pharmacol. 2022 Mar 10;13:849628. doi: 10.3389/fphar.2022.849628. PMID: 35370686; PMCID: PMC8965577.
<sup>21</sup>Abdi M, Lamardi ZH, Shirjan F, Mohammadi L, Abadi SSD, Massoudi N, Zangiabadian M, Nasiri MJ. The Effect of Aspirin on the Prevention of Pro-thrombotic States in Hospitalized COVID-19 Patients: Systematic Review. Cardiovasc Hematol Agents Med Chem. 2022;20(3):189-196. doi: 10.2174/1871525720666220401102728. PMID: 35366783.

<sup>22</sup> Barnes GD, Burnett A, Allen A, Ansell J, Blumenstein M, Clark NP, Crowther M, Dager WE, Deitelzweig SB, Ellsworth S, Garcia D, Kaatz S, Raffini L, Rajasekhar A, Beek AV, Minichiello T. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2022 Aug;54(2):197-210. doi: 10.1007/s11239-022-02643-3. Epub 2022 May 17. PMID: 35579732; PMCID: PMC9111941.

<sup>23</sup> About VHA. Washington, DC: Veterans Health Administration, June 2023.

(https://www.va.gov/health/aboutvha.asp). Accessed July 20, 2023

<sup>24</sup> Wang JZ, Dhanireddy P, Prince C, Larsen M, Schimpf M, Pearman G, Main results report, prepared for Strategic Analysis Service (SAS) Office of Strategic Planning and Analysis (OSPA) Veterans Health Administration. 2021 Survey of Veteran Enrollees' Health and Use of Health Care.

<sup>25</sup>US Department of Veterans Affairs . Corporate data warehouse (CDW). URL:

www.hsrd.research.va.gov/for\_researchers/vinci/cdw.cfm.

<sup>26</sup>Osborne TF, Veigulis ZP, Arreola DM, Röösli E, Curtin CM. Automated EHR score to predict COVID-19 outcomes at US Department of Veterans Affairs. Plos One 2020;15. pmid:32716922

<sup>27</sup>Finh S, Box T. Care Assessment Need (CAN) Score and the Patient Care Assessment System (PCAS): Tools for Care Management https://www.hsrd.research.va.gov/for\_researchers/cyber\_seminars/archives/713-notes.pdf Published 2013. Accessed April 30, 2020.


<sup>28</sup>Albandar HJ, Markert R, Agrawal S. The relationship between aspirin use and mortality in colorectal cancer. Journal of Gastrointestinal Oncology. 2018;9(6):1133–1137 pmid:30603132


<sup>29</sup>Dev S, Gonzalez AA, Coffing J, Slaven JE, Dev S, Taylor S, Ballard C, Hastings SN, Bravata DM. Validating administratively derived frailty scores for use in Veterans Health Administration emergency departments. Acad Emerg Med. 2023 Apr;30(4):349-358. doi: 10.1111/acem.14705. Epub 2023 Mar 28. PMID: 36847429; PMCID: PMC10162447.

<sup>30</sup> Greifer N. Matchlt: Getting started. https://cran.r-project.org/web/packages/Matchlt/vignettes/Matchlt.html. Published June 13, 2023.

<sup>31</sup> Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007 Apr;44(2):62-9. doi: 10.1053/j.seminhematol.2007.02.004. PMID: 17433897; PMCID: PMC2020806.


<sup>32</sup> Bhatt DL, Pollack Jr CV. The Future of Aspirin Therapy in Cardiovascular Disease. The American Journal of Cardiology. 2021 Apr 1;144:S40-7.





Propensity Score Matching applied, matching on the patient variables of age, sex, and CAN score

# Figure



# Figure